id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-P-0895-0003,FDA,FDA-2021-P-0895,Petition Response from FDA CDER to Eagle Pharmaceuticals,Other,Agency Response,2021-12-29T05:00:00Z,2021,12,2021-12-29T05:00:00Z,,2021-12-29T13:27:34Z,,0,0,0900006484f0002f
FDA-2021-P-0895-0002,FDA,FDA-2021-P-0895,Acknowledgment Letter from Eagle Pharmaceuticals,Other,Acknowledgement Letter/Receipt,2021-08-12T04:00:00Z,2021,8,2021-08-12T04:00:00Z,,2021-08-12T19:57:03Z,,0,0,0900006484c4a80f
FDA-2021-P-0895-0001,FDA,FDA-2021-P-0895,Citizen Petition from Eagle Pharmaceuticals,Other,Citizen Petition,2021-08-12T04:00:00Z,2021,8,2021-08-12T04:00:00Z,,2024-11-06T23:50:51Z,,1,0,0900006484c4a80d